High Dose Albumin in Refractory Ascites

Launched by BAYLOR COLLEGE OF MEDICINE · May 10, 2023

Keywords

ClinConnect Summary

**Clinical Trial Summary: High Dose Albumin in Refractory Ascites**

This clinical trial is studying the use of high doses of human albumin in patients with advanced liver disease, specifically those who have a condition called ascites, which is the buildup of fluid in the abdomen. Many patients with liver cirrhosis, a serious liver condition, face challenges when traditional treatments, like medications and dietary changes, do not work well. This study aims to see if giving patients regular doses of albumin can improve their health and help prevent complications related to their liver disease.

To qualify for this trial, participants must be at least 18 years old and have been diagnosed with liver cirrhosis along with refractory ascites, which means their condition hasn't improved despite taking the maximum allowable medications. Participants in the study will receive albumin treatment and will be monitored for safety and effectiveness over time. This trial is important because it could lead to better treatment options for patients who struggle with managing their ascites and improve their overall survival rates. If you or a loved one is experiencing these issues, this could be a potential opportunity to consider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \> 18 years.
• • 2. patients diagnosed with liver cirrhosis.
• • 3. Refractory ascites which is defined as ascites failing to resolve after maximum tolerable dose of diuretics, and usually require frequent paracentesis.
• Exclusion Criteria:
• • 1. Patients \< 18y
• • 2. patients with no history of liver cirrhosis
• • 3. patients with refractory ascites but have transjagular intrahepatic portosystemic shunts (TIPS) with previous 3 months
• • 4. Patients with ascites due to other causes, including cardiac, malignant